FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent

Go back to FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
TRANS-LUX CORPORATION (NASDAQ: TLX) Delayed: 9.67 +0.64 (7.09%)
Previous Close $9.03    52 Week High $2.18 
Open $9.43    52 Week Low $0.30 
Day High $9.69    P/E N/A 
Day Low $9.36    EPS $-3.32 
Volume 531,932